Alpha Emitter Market (By Type of Radionuclide: Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213, Others; By Application: Bone Metastases, Prostate Cancer, Neuroendocrine Tumors, Ovarian Cancer, Others; By Source: Natural Sources (Uranium-238, Radium-226), Artificially Produced Sources (Plutonium, Americium, Curium, Californium), Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Alpha Emitter Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033
8.1.1 Radium (Ra-223)
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Actinium (Ac-225)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Lead (Pb-212)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Astatine-211
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Bismuth-213
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
9.1. Alpha Emitter Market, by Application, 2024-2033
9.1.1. Bone Metastases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Neuroendocrine Tumors
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Ovarian Cancer
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
10.1. Alpha Emitter Market, by Source, 2024-2033
10.1.1. Natural Sources (Uranium-238, Radium-226)
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.1. Alpha Tau Medical Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. NorthStar Medical Radioisotopes
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IBA Worldwide
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. RadioMedix
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Orano Med
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis International AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Actinium Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fusion Pharmaceuticals Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eckert & Ziegler
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client